- Home
- RMCF vs COCP Comparison
RMCF vs COCP Comparison
Compare RMCF & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | COCP |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 15.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | COCP |
|---|---|---|
| Price | $2.18 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 55.8K | ★ 103.2K |
| Earning Date | 01-13-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,638,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $1.12 | $0.90 |
| 52 Week High | $2.38 | $2.67 |
Technical Indicators
Market Signals| Indicator | RMCF | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 48.68 |
| Support Level | $1.96 | $1.00 |
| Resistance Level | $2.25 | $1.19 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 74.53 | 22.68 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).